Systemic Anti-Cancer Therapy Regimen Library
UGI PANC NON-Metastatic - capecitabine chemoradiation [continuous dosing]
Treatment Overview
Commence regimen in relation to radiation therapy as per institutional policy.
Cycles 1 to 6 - 7 days
Cycle details
Cycles 1 to 6 - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration | 1 to 7 | |
| domperidone | 10 mg Three times daily | oral administration | 1 | |
| loperamide | 2 mg | oral administration | 1 |
Full details
Cycles 1 to 6 - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Commence taking capecitabine in relation to radiation therapy when directed by your prescriber. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
|
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
|
| loperamide | 2 mg | oral administration |
Instructions:
Take TWO capsules (=4 mg) at onset of loose bowel motions and a further ONE capsule (=2 mg) for every loose bowel motion (maximum of EIGHT capsules in 24 hours), or use as directed by oncologist or haematologist. |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| capecitabine * | 830 mg/m² Twice daily | oral administration |
Instructions:
Take each dose with food and a large glass of water. Round dose to closest multiple of 150 mg and/or 500 mg tablets. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Diarrhoea risk: | Anti-diarrhoeals are usually prescribed with this treatment |
| Emetogenicity: | Low |
References
Hammel, P., F. Huguet, J. Van Laethem, et al. 2013. “Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.” In ASCO Annual Meeting Proceedings
Huguet, F., P. Hammel, D. Vernerey, et al. 2014. "Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study." ASCO Meeting Abstracts 32(15_suppl):4001
Mukherjee, S., C. Hurt, P. Dutton, et al. 2014. "Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-related quality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial." ASCO Meeting Abstracts 32(15_suppl):4126
Dr Reddy’s New Zealand Ltd. Capercit New Zealand Data Sheet. https://www.medsafe.govt.nz/profs/Datasheet/c/capercittab.pdf (Accessed 16 February 2021).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.